Striking a balance between feasible and realistic biological models

Science Translational Medicine

Volumn 3, Issue 103, 2011, Pages

  Califano, Andrea ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; ERLOTINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

AKT1 GENE; APOPTOSIS; BCL 6 GENE; BCR ABL GENE; BIOLOGICAL MODEL; BREAST CANCER; CANCER CELL CULTURE; CANCER GENETICS; CANCER REGRESSION; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COMPUTER MODEL; DRUG RESPONSE; EGFR GENE; FEASIBILITY STUDY; GENE FUSION; GENE INACTIVATION; HER2 GENE; HUMAN; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE MYC; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SHORT SURVEY; STAT3 GENE; TRANSLATIONAL RESEARCH; TUMOR MODEL; TUMOR SUPPRESSOR GENE;

EID: 80053622510     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003079     Document Type: Short Survey

References (16)

1. P. T. Tran, P. K. Bendapudi, H. J. Lin, P. Choi, S. Koh, J. Chen, G. Horng, N. P. Hughes, L. H. Schwartz, V. A. Miller, T. Kawashima, T. Kitamura, D. Paik, D. W. Felsher, Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci. Transl. Med. 3, 103ra99 (2011).
2. J. Kaiser, Varmus targets 'dysfunction,' scientifi c barriers in cancer research. ScienceInsider (13 July 2010). http:// news.sciencemag.org/ scienceinsider/2010/07/varmustargets- dysfunction.html.
3. I. B. Weinstein, Addiction to oncogenes-The Achilles heal of cancer. Science 297, 63-64 (2002).
4. J. S. Ross, J. A. Fletcher, The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 16, 413-428 (1998).
5. F. Ciardiello, G. Tortora, A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958-2970 (2001).
6. B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, N. B. Lydon, Eff ects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
7. S. V. Sharma, J. Settleman, Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231 (2007).
8. S. Giuriato, S. Ryeom, A. C. Fan, P. Bachireddy, R. C. Lynch, M. J. Rioth, J. Van Riggelen, A. M. Kopelman, E. Passegué, F. Tang, J. Folkman, D. W. Felsher, Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin- 1 to reverse the angiogenic switch. Proc. Natl. Acad. Sci. U.S.A. 103, 16266-16271 (2006).
9. C. H. Wu, J. Van Riggelen, A. Yetil, A. C. Fan, P. Bachireddy, D. W. Felsher, Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. U.S.A. 104, 13028-13033 (2007).
10. +) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485-498 (2010).
11. X. Yang, J. L. Deignan, H. Qi, J. Zhu, S. Qian, J. Zhong, G. Torosyan, S. Majid, B. Falkard, R. R. Kleinhanz, J. Karlsson, L. W. Castellani, S. Mumick, K. Wang, T. Xie, M. Coon, C. Zhang, D. Estrada-Smith, C. R. Farber, S. S. Wang, A. Van Nas, A. Ghazalpour, B. Zhang, D. J. Macneil, J. R. Lamb, K. M. Dipple, M. L. Reitman, M. Mehrabian, P. Y. Lum, E. E. Schadt, A. J. Lusis, T. A. Drake, Validation of candidate causal genes for obesity that aff ect shared metabolic pathways and networks. Nat. Genet. 41, 415-423 (2009).
12. C. Lefebvre, P. Rajbhandari, M. J. Alvarez, P. Bandaru, W. K. Lim, M. Sato, K. Wang, P. Sumazin, M. Kustagi, B. C. Bisikirska, K. Basso, P. Beltrao, N. Krogan, J. Gautier, R. Dalla-Favera, A. Califano, A human B-cell interactome identifi es MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol. 6, 377 (2010).
13. X. Zhao, D. D' Arca, W. K. Lim, M. Brahmachary, M. S. Carro, T. Ludwig, C. C. Cardo, F. Guillemot, K. Aldape, A. Califano, A. Iavarone, A. Lasorella, The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Dev. Cell 17, 210-221 (2009).
14. K. Wang, M. Saito, B. C. Bisikirska, M. J. Alvarez, W. K. Lim, P. Rajbhandari, Q. Shen, I. Nemenman, K. Basso, A. A. Margolin, U. Klein, R. Dalla-Favera, A. Califano, Genome-wide identifi cation of post-translational modulators of transcription factor activity in human B cells. Nat. Biotechnol. 27, 829-839 (2009).
15. M. S. Carro, W. K. Lim, M. J. Alvarez, R. J. Bollo, X. Zhao, E. Y. Snyder, E. P. Sulman, S. L. Anne, F. Doetsch, H. Colman, A. Lasorella, K. Aldape, A. Califano, A. Iavarone, The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325 (2010).
16. S. L. Schreiber, A. F. Shamji, P. A. Clemons, C. Hon, A. N. Koehler, B. Munoz, M. Palmer, A. M. Stern, B. K. Wagner, S. Powers, S. W. Lowe, X. Guo, A. Krasnitz, E. T. Sawey, R. Sordella, L. Stein, L. C. Trotman, A. Califano, R. Dalla-Favera, A. Ferrando, A. Iavarone, L. Pasqualucci, J. Silva, B. R. Stockwell, W. C. Hahn, L. Chin, R. A. DePinho, J. S. Boehm, S. Gopal, A. Huang, D. E. Root, B. A. Weir, D. S. Gerhard, J. C. Zenklusen, M. G. Roth, M. A. White, J. D. Minna, J. B. MacMillan, B. A. Posner; Cancer Target Discovery and Development Network, Towards patient-based cancer therapeutics. Nat. Biotechnol. 28, 904-906 (2010).